AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01909141 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound
Description: transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of > 18 mm or till day 20 of the cycle
Study NCT01909141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: body mass index (BMI) calculation
Description: BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
Study NCT01909141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone
Description: baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
Study NCT01909141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pretreatment blood urea and serum creatinine
Description: blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
Study NCT01909141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serum estradiol (E2) on day 12
Description: serum E2 will be assayed on day 12 of the cycle for all women.
Study NCT01909141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: serum progesterone on day 21
Description: serum progesterone will be assayed on day 21 for all women to monitor ovulation.
Study NCT01909141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood urea and serum creatinine every month
Description: blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
Study NCT02077309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Study NCT02077309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00074815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serotonin reuptake inhibitors management
Description: Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI.
Study NCT00074815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors management
Description: Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI.
Study NCT03283878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA for Group 1.~Cefazolin will be administered intravenously within less than 60 minutes prior to skin incision in elective TKA. In addition, two weight based doses of cefazolin will be administered within 24 hours postoperatively for Group 2.
Study NCT00074815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy by a psychologist
Description: CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care
Study NCT03199651 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of tumor tissue and blood sample for repository
Study NCT03199651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tumor tissue and blood sample for AGIT/DS
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Chart Review
Description: Undergo medical record abstraction
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Undergo medical record abstraction
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03199651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03199651 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Intervention
Description: Undergo usual care or NCCN-driven CTC/DS
Study NCT03199651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: Undergo usual care or NCCN-driven CTC/DS
Study NCT03913481 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution
Description: In the ANH arm, after induction of general anesthesia, a total blood volume of at least 650 ml of blood will be drawn from a central line. The amount of volume drawn can be replaced with Ringer lactate or a similar crystalloid fluid up to a 3:1 ratio.
Study NCT03913481 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: Best available treatment without ANH
Study NCT01272037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT01272037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT01272037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00074815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructional cognitive behavioral therapy by a psychiatrist
Description: The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy.
Study NCT03247088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic HSCT IV
Study NCT03247088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01272037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT01272037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies (closed as of 12/1/12)
Study NCT01272037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemotherapy
Description: Given IV
Study NCT01272037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study NCT03247088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT03945552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Interaction Project
Description: VIP is a strengths-based, family-centered intervention that uses pediatric well-child visits to enhance parenting practices/relationships and child development by promoting positive parenting practices such as pretend play, shared reading, and daily routines.
Study NCT03247088 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT03247088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03247088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO
Study NCT02923570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon intensity modulated radiation therapy (IMRT)
Description: Photon intensity modulated radiation therapy (IMRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
Study NCT02923570 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton beam radiotherapy (PBRT)
Description: Proton beam radiotherapy (PBRT) to standard dose of 60-66Gy in standard 2 Gy per fraction.
Study NCT03221517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized meal with a glucose challenge test
Description: Postprandial glucose and insulin response
Study NCT02149030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cytological screening in A1 and A3
Description: Cytological screening.
Study NCT02149030 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cytological screening in A1 and A3
Description: Cytological screening.
Study NCT03997123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg (2 oral tablets) given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week off-treatment within each 28-day treatment cycle. Study treatment will be continued until disease progression unless there is evidence of unacceptable toxicity, or if the patient requests to stop the study treatment.
Study NCT03997123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
Study NCT03997123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 concentrate for solution for infusion, 3 consecutive weekly infusions of 80 mg/m2 (given on Day 1 of Weeks 1, 2, and 3), followed by 1 week off-treatment within each 28-day treatment cycle. Paclitaxel treatment will be continued for at least 6 cycles unless the patient experiences unacceptable toxicity that is attributed directly to treatment with paclitaxel.
Study NCT03997123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
Study NCT03986931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Pharmacist-Bidirectional Texting Group
Description: The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.
Study NCT03986931 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Control Group
Description: This group will receive bidirectional texting, but no pharmacist monitoring.
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV or PO
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT01424982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib Hydrochloride
Description: Given PO
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT01424982 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV
Study NCT01424982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00569127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00569127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00569127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide Acetate
Description: Given IM
Study NCT00569127 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given SC
Study NCT02551068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60% Oxygen
Description: While participants are exercising, they will be inhaling 60% oxygen through a mask
Study NCT02551068 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
Study NCT03741127 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rimiducid may be administered as indicated
Description: Patients who received P-BCMA-101 in a previous trial will be evaluated in this trial for long term safety and efficacy. Rimiducid (safety switch activator) may be administered as indicated.
Study NCT03462719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.
Study NCT03462719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.
Study NCT03462719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.
Study NCT03462719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.
Study NCT03462719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (as Subsequent Therapy)
Description: Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
Study NCT03462719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib (as Subsequent Therapy)
Description: Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.
Study NCT01621581 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Convection enhanced delivery/AAV2-GDNF
Description: Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery
Study NCT03928093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin /placebo capsules will be taken by mouth and will be prescribed for the study participants in the doses, depending on their weight and treatment phase: Participant \< 25 kg at baseline will start with 50 mg per day, increasing the dose by 50 mg each week until their maximum dose 200 mg per day; Participants who are greater than or equal to 25 kg at baseline will start with 100 mg per day, increasing their dose by 50 mg each week until their target dose 300 mg per day is achieved. The study medication will be taken twice per day.The dose will be weaned down every 1-2 days by 25 mg in the last two weeks of each treatment period.
Study NCT03012971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine supplemented morphine analgesia
Description: Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
Study NCT03012971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine analgesia
Description: Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. 5-HT3 receptor antagonist is added when necessary. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
Study NCT03247088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT03247088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given PO
Study NCT03066830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin (SAR439954)
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03066830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03066830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT03066830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulfonylurea
Description: Pharmaceutical form: tablet~Route of administration: oral
Study NCT01794962 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive functional therapy
Description: The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
Study NCT04512430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Patients will receive 1200 mg of Atezolizumab every 21 days (QW3) (+/- 3 days) during neoadjuvant phase and every 28 days (QW4) (+/- 3 days) at adjuvant phase in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.~First Infusion~* No premedication administered for atezolizumab specifically is permitted~* Infuse atezolizumab (1200 mg in a 250 mL 0.9% NaCl IV bag) over 60 (+/- 15) minutes.~Subsequent Infusions:~* If patient experienced infusion-related reaction during any previous infusion, premedication with antihistamines may be administered for Cycles > 2 at the discretion of the treating physician.~* If the patient tolerated the first infusion well without infusion-associated adverse events, the successive infusion may be delivered over 30 (+/- 10) minutes.
Study NCT04512430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days, for 3 cycles during neoadjuvant phase, in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.